Financials in USD. Standardized financial statements.
A compact view of how Institute of Biomedical Research Corp. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $49,487 | $45,074 | $29,444 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +9.8% | +53.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $28,085 | $36,525 | $20,770 | $0 | $0 | $0 | $0 | $1.25M | $786,105 | $0 |
| Gross Profit? | $21,402 | $8,549 | $8,674 | $0 | $0 | $0 | $0 | -$1.25M | -$786,105 | $0 |
| Gross Margin? | +43.2% | +19.0% | +29.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $777,915 | $1.80M | $732,549 | $167,005 | $44,238 | $261,726 | $426,795 | $4.08M | $33,379 | $133,751 |
| Operating Income? | -$756,513 | -$1.80M | -$723,875 | -$167,005 | -$44,238 | -$261,726 | -$426,795 | -$5.37M | -$819,484 | -$133,751 |
| EBITDA? | -$724,260 | $1.39M | -$384,102 | -$167,005 | -$44,238 | -$239,150 | -$239,150 | -$398,781 | -$5.32M | -$95,032 |
| Income Before Tax | -$739,640 | $1.36M | -$433,406 | -$167,005 | -$44,238 | -$273,402 | -$443,288 | -$5.37M | -$827,568 | $176,881 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $32,986 | $71,298 | -$129,163 | $43,130 |
| Net Income? | -$632,720 | $1.33M | -$433,406 | -$167,005 | -$44,238 | -$273,402 | -$443,288 | -$5.37M | -$690,299 | -$176,881 |
| EPS? | $-0.00 | $0.00 | $-0.00 | $-0.00 | $0.00 | $-0.05 | $-0.09 | $-1.88 | $-0.39 | $-0.13 |
| Diluted EPS? | $-0.00 | $0.00 | $-0.00 | $-0.00 | $0.00 | $-0.05 | $-0.09 | $-1.88 | $-0.39 | $-0.13 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality